Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04216394 · ClinicalTrials.gov registry record
Anticoagulation in Emergency General Surgery
A clinical trial of Emergency General Surgery, sponsored by Methodist Health System.
- Completed
- Registry status
- 4
- Enrollment target
- 1
- Study location
NCT04216394: Completed study of Emergency General Surgery, sponsored by Methodist Health System.
NCT04216394 is a study of Emergency General Surgery that has completed, run by Methodist Health System. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04216394, a study of Emergency General Surgery, has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the EGS population taking DOACs. We hypothesize that patients taking a DOAC will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in EGS patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.
Primary Outcome
To determine the bleeding risk and need for unplanned intervention
Conditions Studied
Interventions
- PROCEDURE Emergency general surgery
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2020-11-13 |
What the finished NCT04216394 record still lists
NCT04216394 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 1 condition, with Emergency General Surgery appearing as the primary indexed condition, and to 1 intervention - of which Emergency general surgery is the first listed.
NCT04216394 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04216394 about?
NCT04216394 is a clinical study titled "Anticoagulation in Emergency General Surgery". While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outc...
What is the current status of trial NCT04216394?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2019-10-31. Estimated completion is 2020-11-13.
What conditions does trial NCT04216394 study?
This clinical trial studies the following conditions: Emergency General Surgery.
What interventions are being tested in trial NCT04216394?
The interventions under investigation include: Emergency general surgery (PROCEDURE).
Who is sponsoring clinical trial NCT04216394?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04216394 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI